Objective To examine the risk of treatment emergent, cardiovascular serious adverse events
associated with varenicline use for tobacco cessation. Design Meta-analysis comparing …

In this article, the authors briefly review the pharmacotherapeutic agents that are currently
available for the treatment of substance use disorders. Nicotine replacement therapies are …

Tobacco dependence is the most common substance use disorder in adults with mental
illness. The prevalence rates for tobacco dependence are two to four times higher in these …

Tobacco use is the leading preventable cause of death worldwide. Stopping tobacco use
benefits virtually every smoker. Most of the 19% of US residents who smoke want to quit and …

Background Varenicline is an efficacious smoking‐cessation drug. However, previous meta‐
analyses provide conflicting results regarding its cardiovascular safety. The publication of …

Treating tobacco dependence is the most effective way to reduce tobacco-related death and
disability. Counseling and pharmacotherapy have been shown to increase tobacco …

Tobacco use remains the most important worldwide cause of preventable death due mainly
to cancer, cardiovascular disease, and chronic lung disease. If the current tobacco …

Review: Varenicline increases risk for serious adverse cardiovascular events in tobacco users |
Annals of Internal Medicine Advertisement ACP Online Annals of Internal Medicine Annals of …

The risk of adverse cardiovascular events from varenicline reasonable long-term time
horizon in order to frame the expected smoking cessation benefits. While we could choose …

Résumé Introduction: le tabac est une cause majeure de maladie et la première cause de
mort évitable dans le monde. Son arrêt permet de réduire la surmortalité qui lui est associée …